RBBP4 and prostate adenocarcinoma: Concomitantly, using the tools and statistics available through cBioportal (http://www.cbioportal.org/, accessed on 3 March 2021) we found a positive correlation between high levels of expression of five components of the NuRD complex (RBBP4, RBBP7, HDAC1, HDAC2 and MTA2) and a shorter progression free survival, with a logrank test p-value of 0.018, in the prostate adenocarcinoma (acinar type) study (TCGA PanCancer Atlas), integrated by 494 patients (Figure 3D).